Search

everythinglearnresearchcommunity

for

Search:↓

Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.

A woman's complete hair loss condition improved after recovering from COVID-19.

HIV-positive pregnant women are more likely to experience severe bleeding, and a pregnant woman with familial hypertriglyceridemia had a successful early delivery with special care.

Most children recovered from COVID-19 in 4 weeks, but some experienced long-term symptoms, especially older kids.

Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.

Many patients experienced hair loss after COVID-19, with women affected more, starting on average 49 days post-infection.

One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.

Low ferritin and Vitamin D levels may cause hair loss after COVID-19.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

To treat tinea capitis in children, oral antifungal medication is necessary, with newer drugs offering shorter treatment times than the traditional griseofulvin.

Fiber implantation for baldness is not recommended because it causes many problems and doesn't work well.

The document concludes that various childhood hair and nail disorders exist, some may improve on their own, and advances in genetics and immunology could enhance treatment and counseling.

COVID-19 infection may cause hair loss.

Certain skin symptoms in COVID-19 patients may indicate a more severe illness.

A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.

Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.

Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

COVID-19 can cause skin issues like chilblains and rashes, which may help in early detection, especially in patients without other symptoms.

COVID-19 can cause skin problems and affect dermatology treatments, with recommendations for skin care and cautious use of certain drugs.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Pregnancy can change skin disease severity, with some conditions improving and others worsening, and treatment should balance benefits and fetal safety.

Wait 3 months after COVID-19 before trying assisted reproduction and further research is needed on COVID-19's effects on male hormones and fertility.

Androgens may worsen COVID-19 and hair loss could indicate the disease's severity.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Long COVID in Japan involves persistent symptoms like fatigue and may be caused by lasting organ damage and prolonged inflammation, with vaccination as a potential treatment.

Many women who have used performance-enhancing drugs in Finland show high rates of mental health and substance use issues, and most have normal red blood cell counts.

COVID-19 diagnosis is linked to new or worsening hair diseases, with stress from the pandemic likely contributing.

Most hospitalized COVID-19 survivors in the study experienced long-term symptoms, affecting their daily life and mental functions.

COVID-19 can cause skin symptoms that might help spot the virus early, and treatments for it can also affect the skin.